nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Blood Predictive Biomarkers for Patients With Non–small-cell Lung Cancer Associated With Clinical Response to Nivolumab
|
Agulló-Ortuño, M. Teresa |
|
|
21 |
1 |
p. 75-85 |
artikel |
2 |
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
|
Dal Maso, Alessandro |
|
|
21 |
1 |
p. 1-14.e3 |
artikel |
3 |
Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma
|
Mattar, Marissa S. |
|
|
21 |
1 |
p. e25-e29 |
artikel |
4 |
Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non–Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France)
|
Heeke, Simon |
|
|
21 |
1 |
p. 56-65.e8 |
artikel |
5 |
Development and Validation of a 18F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy
|
Guo, Hao-Yue |
|
|
21 |
1 |
p. 47-55 |
artikel |
6 |
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma
|
Doi, Hiroshi |
|
|
21 |
1 |
p. 66-74.e2 |
artikel |
7 |
Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non–small-cell Lung Cancer
|
Al-Obeidi, Ebaa |
|
|
21 |
1 |
p. e15-e20 |
artikel |
8 |
Editorial Board
|
|
|
|
21 |
1 |
p. A1 |
artikel |
9 |
Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis
|
Widick, Page |
|
|
21 |
1 |
p. e6-e9 |
artikel |
10 |
Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non–Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm
|
Bover, Mateo |
|
|
21 |
1 |
p. e1-e5 |
artikel |
11 |
Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non–Small-Cell Lung Cancer
|
Mitchell, Kyle G. |
|
|
21 |
1 |
p. 37-46.e7 |
artikel |
12 |
Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation
|
Tsutsumi, Hirono |
|
|
21 |
1 |
p. e21-e24 |
artikel |
13 |
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial
|
Bennouna, Jaafar |
|
|
21 |
1 |
p. e10-e14 |
artikel |
14 |
Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy
|
Castello, Angelo |
|
|
21 |
1 |
p. 28-36 |
artikel |
15 |
QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care
|
Le, Tri |
|
|
21 |
1 |
p. 21-27.e5 |
artikel |
16 |
Response to Letter to the Editor Titled “Surgery or Stereotactic Body Radiotherapy for Early Stage Lung Cancer: What is the Current Evidence?”
|
Scotti, Vieri |
|
|
21 |
1 |
p. e35-e36 |
artikel |
17 |
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)
|
Chiari, Rita |
|
|
21 |
1 |
p. 15-20 |
artikel |
18 |
Successful Retreatment Using Pembrolizumab for Non–small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report
|
Kobayashi, Keigo |
|
|
21 |
1 |
p. e30-e32 |
artikel |
19 |
Surgery or Stereotactic Body Radiotherapy for Early-stage Lung Cancer: What Is the Current Evidence?
|
Deng, Han-Yu |
|
|
21 |
1 |
p. e33-e34 |
artikel |
20 |
Table of Contents
|
|
|
|
21 |
1 |
p. A2-A3, A13, A15 |
artikel |
21 |
Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience
|
Franceschini, Davide |
|
|
21 |
1 |
p. 86-93 |
artikel |